Cuban Joins Trump at TrumpRx to Add 600 Generics via Cost Plus, Amazon, GoodRx: Why Cash Pricing That Skips Deductibles Misses Most Insured Americans & How PBM Formulary Threats Block Brand Adoption
Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
Video Preview
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
The Monday Photo Op No One Predicted
What TrumpRx Actually Is Under the Hood
The Deductible Trap and the 85 Percent Problem
Why Cuban Has Been Locked Out of Brand Drugs
The Employer Formulary Problem
The Generic Math, Including What the Studies Say
The Good, the Bad, the Ugly
So Will This Actually Work
Abstract
Monday 5/18/26: WH announces TrumpRx expansion w/ Mark Cuban Cost Plus Drugs, Amazon Pharmacy, GoodRx, adding 600+ generics on top of the original 43-brand-name Feb 2026 launch.
TrumpRx is a coupon aggregator, not a pharmacy. Routes patients to manufacturer DTC sites or generates coupons for retail pickup. Built on GoodRx tech.
Cash-pay only. Purchases generally don’t count toward deductibles or OOP maxes. Not accepted in CA or MA. Most manufacturer DTC deals exclude Medicare, Medicaid, TRICARE, VA enrollees.
KFF and STAT analyses: for the ~85% of Americans with Rx coverage, insurance copays will usually beat TrumpRx cash prices, especially once deductibles are met. Real beneficiaries: uninsured (~8% under 65), high-deductible patients who never hit their deductible, and patients with non-covered drugs (GLP-1s for weight, IVF, fertility).
Cost Plus model: drug cost + 15% markup + $5 pharmacy labor + $5.25 shipping. Cuban added ~500 generics to TrumpRx.
Big 3 PBMs (CVS Caremark, Express Scripts, OptumRx) control ~90% of US Rx claims per FTC 2024 report. Cuban’s struggle on brands is structural: PBMs threaten manufacturers w/ portfolio-wide formulary deprioritization if they sell to Cost Plus at competitive brand pricing.
Employer channel struggle = rebate addiction + contracting complexity + network access. Humana CenterWell partnership (April 2026) is Cuban’s workaround.
FTC settlement w/ Express Scripts requires “covered access to TrumpRx as part of its standard offering upon relevant legal and regulatory changes.” Potential wedge to fix the deductible-credit problem.
Net read: Generic expansion is a real win for cash-pay segment. For 85% of insured, math still favors insurance. Real reform is upstream of the website.
The Monday Photo Op No One Predicted
Mark Cuban standing in the Roosevelt Room next to Donald Trump on May 18, 2026, was not on anyone’s bingo card last year. Cuban spent the 2024 cycle campaigning for Kamala Harris, calling Trump’s economic ideas incoherent, and going on every podcast that would have him to argue the case. Trump, asked about Cuban’s appearance Monday, told reporters Cuban had made “a big mistake” in 2024, then went on to praise Cost Plus Drugs as one of the best things to happen to American patients. Cuban, in turn, told Newsweek after the event, “Anything that reduces the cost of medications for Republicans, independents, and Democrats is a win. I’ll align with anybody, I don’t care. If you’re going to make healthcare cheaper, you’re my new best friend.”
That’s a clean summary of the politics, and also a useful reminder that drug pricing breaks party lines in weird ways. Both ends of the spectrum want to swing at the same PBM piñata. It also signals where Cuban thinks his actual leverage sits: not in fighting CVS Caremark or OptumRx through op-eds, but in plugging Cost Plus into whatever distribution rails happen to have eyeballs and government endorsement attached. TrumpRx is the largest single distribution channel on offer that doesn’t require running through a vertically integrated PBM-insurer. So he plugged in.
Standing next to Cuban Monday were execs from Amazon Pharmacy and GoodRx, plus HHS adviser Chris Klomp (one of the original TrumpRx architects) and CMS Administrator Mehmet Oz. Oz repeated the MAHA-friendly stat that almost one in three Americans, when they go to a drugstore, cannot afford to pick up the medications their doctor prescribed. The number is directionally supported by various access surveys, but adherence drop-off can come from copays, prior auth, step therapy, formulary exclusions, and pure cash-pay all at once. TrumpRx only addresses the cash-pay piece, which is the smallest of those buckets for most insured patients.
What TrumpRx Actually Is Under the Hood
